ReviewNanomedicine (London, England)2025
Application of pre-amplification-based CRISPR-Cas nanostructured biosensors for bacterial detection.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A novel tripod probe and lateral flow test to improve CRISPR/Cas12a assay: benefits of branched probe based on trebler phosphoramidite modification.Mikrochimica acta · 2025Article
- CRISPR-driven diagnostics: Molecular mechanisms, clinical efficacy and translational challenges.Clinical and translational medicine · 2025Review
- One-Pot Isothermal Nucleic Acid Amplification Assisted CRISPR/Cas Detection Technology: Challenges, Strategies, and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections are one of the primary triggers of global disease outbreaks. Traditional detection methods, such as bacterial culture and PCR, while reliable, are limited by their time-consuming procedures and operational complexity. In recent years, the CRISPR-Cas system has demonstrated significant potential in gene editing and diagnostics due to its high specificity and precision, offering innovative solutions for bacterial detection. By integrating pre-amplification techniques, the CRISPR-Cas system has substantially enhanced detection sensitivity, particularly excelling in detecting low-concentration target bacteria. This review summarizes the principles and application examples of CRISPR-Cas-based fluorescence, electrochemical, lateral flow, and colorimetric nanostructured biosensors developed over the past three years, categorizing them according to their recognition methods (e.g. bacterial genomes, aptamers, antibodies). It systematically explores the broad application prospects of these sensors in medical diagnostics, environmental monitoring, and food safety assessment. Additionally, this review discusses future research directions and potential development prospects, providing new insights and technical support for the rapid diagnosis and treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.